1. By:
Armin Eisazaei, II Pharm.D
Al Ameen College of Pharmacy,Bangalore_560027

2. 



INTRODUCTION

3. 


Epidemiology

4. 



5. 



Signs of leprosy

6. 



Symptoms

7. 

 Indeterminate leprosy:
Types of leprosy

8. 
Indeterminate leprosy:

9. 
 A few hypopigmented macules, some are large and
some become anesthetic (lose pain sensation) some
neural involvement in which nerves become
enlarged;
spontaneous resolution in a few years, persists or
advances to other forms.
Tuberculoid leprosy

10. 
Tuberculoid leprosy

11. 

Borderline tuberculoid leprosy

12. 
Borderline tuberculoid leprosy

13. 

.
Borderline lepromatous leprosy

14. 
Borderline lepromatous leprosy

15. 

.
Mid-borderline leprosy

16. 
Mid-borderline leprosy

17. 

Lepromatous leprosy

18. 
Lepromatous leprosy

19. 

Pathology

20. 


21. 






•
Transmission

22. 



Who is at risk?

23. 







24. 





.

25. 





26. 
 :
1) Early detection of patients
2) Appropriate treatment
3) Adequate care for the prevention of disabilities and
rehabilitation

27. 






.

28. 



29. 
M.O.A:
PK:
ADRs:
Dapsone

30. 

 M.O.A:
 • Specific inhibitors of bacterial RNA polymerase
 • Acts by binding to and inhibiting DNA dependent
RNA polymerase
 • Active against gram + ve and may be gram – ve
species.

31. 












32. 



33. •
M.O.A:
PK
ADRs:

34. 
RFP Dapsone
Adult 50-70kg 600mg/m 100mg/d
Child 10-14 years 450mg/m 50mg/d
‘’Less than 10 years’’ 300mg/m 25mg/d
Multidrug Therapy for Paucibacillary (PB) Leprosy

35. 
RFP Dapsone CLF
Adult 50-70kg 600mg/m 100mg/d 50mg/d
&300mg/m
Child 10-14 years 450mg/m 50mg/d 50mg/d &
150mg/m
Less than 10 years 300mg/m 25mg/d 50mg twice/d
&100mg/m
Multidrug Therapy for Multibacillary (MB)
Leprosy

36. 
 • Harissons
 • Rang and Dale
 • CIMS
References:

37. Good Luck…